Dataset from A Randomized, Open-label, Single-dose, Parallel-arm, Single-center, Phase 1 Study to Determine the Bioavailability of Lanadelumab Administered Subcutaneously With the Prefilled Syringe and the Autoinjector in Healthy Adult Volunteer Subjects
收藏NIAID Data Ecosystem2026-05-02 收录
下载链接：
https://doi.org/10.25934/PR00009405
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this study is to evaluate bioavailability of lanadelumab (SHP643) following a
single, 2 milliliter (mL) subcutaneous (SC) dose of 300 milligrams (mg) delivered by
prefilled syringe (PFS) or auto injector (AI) in healthy adult participants.
创建时间：
2024-11-26
